A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma. Grommes C, Nandakumar S, Schaff LR, Gavrilovic I, et al. Clin Cancer Res 2024;30:4005-4015.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Grommes C, Nandakumar S, Schaff LR, Gavrilovic I, et al. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma. Clin Cancer Res 2024;30:4005-4015.
PMID: 38995739